{"pmid":32360182,"title":"Antiviral activities of type I interferons to SARS-CoV-2 infection.","text":["Antiviral activities of type I interferons to SARS-CoV-2 infection.","There is an urgent need to identify antivirals to curtail the COVID-19 pandemic. Herein, we report the sensitivity of SARS-CoV-2 to recombinant human interferons alpha and beta (IFNalpha/beta). Treatment with IFN-alpha or IFN-beta at a concentration of 50 international units (IU) per milliliter reduces viral titers by 3.4 log or over 4 log, respectively, in Vero cells. The EC50 of IFN-alpha and IFN-beta treatment is 1.35 IU/ml and 0.76 IU/ml, respectively, in Vero cells. These results suggest that SARS-CoV-2 is more sensitive than many other human pathogenic viruses, including SARS-CoV. Overall, our results demonstrate the potential efficacy of human Type I IFN in suppressing SARS-CoV-2 infection, a finding which could inform future treatment options for COVID-19.","Antiviral Res","Mantlo, Emily","Bukreyeva, Natalya","Maruyama, Junki","Paessler, Slobodan","Huang, Cheng","32360182"],"abstract":["There is an urgent need to identify antivirals to curtail the COVID-19 pandemic. Herein, we report the sensitivity of SARS-CoV-2 to recombinant human interferons alpha and beta (IFNalpha/beta). Treatment with IFN-alpha or IFN-beta at a concentration of 50 international units (IU) per milliliter reduces viral titers by 3.4 log or over 4 log, respectively, in Vero cells. The EC50 of IFN-alpha and IFN-beta treatment is 1.35 IU/ml and 0.76 IU/ml, respectively, in Vero cells. These results suggest that SARS-CoV-2 is more sensitive than many other human pathogenic viruses, including SARS-CoV. Overall, our results demonstrate the potential efficacy of human Type I IFN in suppressing SARS-CoV-2 infection, a finding which could inform future treatment options for COVID-19."],"journal":"Antiviral Res","authors":["Mantlo, Emily","Bukreyeva, Natalya","Maruyama, Junki","Paessler, Slobodan","Huang, Cheng"],"date":"2020-05-04T11:00:00Z","year":2020,"_id":"32360182","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.antiviral.2020.104811","keywords":["antiviral therapy","covid-19","innate immune","interferon","sars-cov-2"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138495505137667,"score":9.490897,"similar":[{"pmid":32464097,"title":"Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19.","text":["Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19.","Coronavirus disease 2019 (COVID-19) is a global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Without approved antiviral therapeutics or vaccines to this ongoing global threat, type I and type III interferons (IFNs) are currently being evaluated for their efficacy. Both the role of IFNs and the use of recombinant IFNs in two related, highly pathogenic coronaviruses, SARS-CoV and MERS-CoV, have been controversial in terms of their protective effects in the host. In this review, we describe the recent progress in our understanding of both type I and type III IFN-mediated innate antiviral responses against human coronaviruses and discuss the potential use of IFNs as a treatment strategy for COVID-19.","Cell Host Microbe","Park, Annsea","Iwasaki, Akiko","32464097"],"abstract":["Coronavirus disease 2019 (COVID-19) is a global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Without approved antiviral therapeutics or vaccines to this ongoing global threat, type I and type III interferons (IFNs) are currently being evaluated for their efficacy. Both the role of IFNs and the use of recombinant IFNs in two related, highly pathogenic coronaviruses, SARS-CoV and MERS-CoV, have been controversial in terms of their protective effects in the host. In this review, we describe the recent progress in our understanding of both type I and type III IFN-mediated innate antiviral responses against human coronaviruses and discuss the potential use of IFNs as a treatment strategy for COVID-19."],"journal":"Cell Host Microbe","authors":["Park, Annsea","Iwasaki, Akiko"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32464097","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.chom.2020.05.008","topics":["Treatment","Mechanism"],"weight":1,"_version_":1668079521320927232,"score":308.0749},{"pmid":32152082,"pmcid":"PMC7179632","title":"Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus.","text":["Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus.","Currently, the expansion of the novel human respiratory coronavirus (known as SARS-CoV-2 [severe acute respiratory syndrome coronavirus 2], COVID-2019 [coronavirus disease 2019], or 2019-nCoV [2019 novel coronavirus]) has stressed the need for therapeutic alternatives to alleviate and stop this new epidemic. The previous epidemics of infections by high-morbidity human coronaviruses, such as SARS-CoV in 2003 and the Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012, prompted the characterization of compounds that could be potentially active against the currently emerging novel coronavirus, SARS-CoV-2. The most promising compound is remdesivir (GS-5734), a nucleotide analog prodrug currently in clinical trials for treating Ebola virus infections. Remdesivir inhibited the replication of SARS-CoV and MERS-CoV in tissue cultures, and it displayed efficacy in nonhuman animal models. In addition, a combination of the human immunodeficiency virus type 1 (HIV-1) protease inhibitors lopinavir/ritonavir and interferon beta (LPV/RTV-IFN-beta) was shown to be effective in patients infected with SARS-CoV. LPV/RTV-IFN-beta also improved clinical parameters in marmosets and mice infected with MERS-CoV. Remarkably, the therapeutic efficacy of remdesivir appeared to be superior to that of LPV/RTV-IFN-beta against MERS-CoV in a transgenic humanized mouse model. The relatively high mortality rates associated with these three novel human coronavirus infections, SARS-CoV, MERS-CoV, and SARS-CoV-2, have suggested that proinflammatory responses might play a role in the pathogenesis. It remains unknown whether the generated inflammatory state should be targeted. Therapeutics that target the coronavirus alone might not be able to reverse highly pathogenic infections. This minireview aims to provide a summary of therapeutic compounds that have shown potential in fighting SARS-CoV-2 infections.","Antimicrob Agents Chemother","Martinez, Miguel Angel","32152082"],"abstract":["Currently, the expansion of the novel human respiratory coronavirus (known as SARS-CoV-2 [severe acute respiratory syndrome coronavirus 2], COVID-2019 [coronavirus disease 2019], or 2019-nCoV [2019 novel coronavirus]) has stressed the need for therapeutic alternatives to alleviate and stop this new epidemic. The previous epidemics of infections by high-morbidity human coronaviruses, such as SARS-CoV in 2003 and the Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012, prompted the characterization of compounds that could be potentially active against the currently emerging novel coronavirus, SARS-CoV-2. The most promising compound is remdesivir (GS-5734), a nucleotide analog prodrug currently in clinical trials for treating Ebola virus infections. Remdesivir inhibited the replication of SARS-CoV and MERS-CoV in tissue cultures, and it displayed efficacy in nonhuman animal models. In addition, a combination of the human immunodeficiency virus type 1 (HIV-1) protease inhibitors lopinavir/ritonavir and interferon beta (LPV/RTV-IFN-beta) was shown to be effective in patients infected with SARS-CoV. LPV/RTV-IFN-beta also improved clinical parameters in marmosets and mice infected with MERS-CoV. Remarkably, the therapeutic efficacy of remdesivir appeared to be superior to that of LPV/RTV-IFN-beta against MERS-CoV in a transgenic humanized mouse model. The relatively high mortality rates associated with these three novel human coronavirus infections, SARS-CoV, MERS-CoV, and SARS-CoV-2, have suggested that proinflammatory responses might play a role in the pathogenesis. It remains unknown whether the generated inflammatory state should be targeted. Therapeutics that target the coronavirus alone might not be able to reverse highly pathogenic infections. This minireview aims to provide a summary of therapeutic compounds that have shown potential in fighting SARS-CoV-2 infections."],"journal":"Antimicrob Agents Chemother","authors":["Martinez, Miguel Angel"],"date":"2020-03-11T11:00:00Z","year":2020,"_id":"32152082","source":"PubMed","week":"202011|Mar 09 - Mar 15","doi":"10.1128/AAC.00399-20","keywords":["sars-cov-2","antiviral agents","coronavirus"],"e_drugs":["remdesivir","lopinavir-ritonavir drug combination"],"topics":["Treatment"],"weight":1,"_version_":1666138492705439744,"score":296.22763},{"pmid":32456286,"title":"Antiviral Effects of Hydroxychloroquine and Type I Interferon on In Vitro Fatal Feline Coronavirus Infection.","text":["Antiviral Effects of Hydroxychloroquine and Type I Interferon on In Vitro Fatal Feline Coronavirus Infection.","Feline infectious peritonitis (FIP) is a viral disease with a high morbidity and mortality by the FIP virus (FIPV, virulent feline coronavirus). Several antiviral drugs for FIP have been identified, but many of these are expensive and not available in veterinary medicine. Hydroxychloroquine (HCQ) is a drug approved by several countries to treat malaria and immune-mediated diseases in humans, and its antiviral effects on other viral infections (e.g., SARS-CoV-2, dengue virus) have been confirmed. We investigated whether HCQ in association with interferon-omega (IFN-omega) is effective for FIPV in vitro. A total of 100 muM of HCQ significantly inhibited the replication of types I and II FIPV. Interestingly, the combination of 100 muM of HCQ and 10(4) U/mL of recombinant feline IFN-omega (rfIFN-omega, veterinary registered drug) increased its antiviral activity against type I FIPV infection. Our study suggested that HCQ and rfIFN-omega are applicable for treatment of FIP. Further clinical studies are needed to verify the combination of HCQ and rIFN-omega will be effective and safe treatment for cats with FIP.","Viruses","Takano, Tomomi","Satoh, Kumi","Doki, Tomoyoshi","Tanabe, Taishi","Hohdatsu, Tsutomu","32456286"],"abstract":["Feline infectious peritonitis (FIP) is a viral disease with a high morbidity and mortality by the FIP virus (FIPV, virulent feline coronavirus). Several antiviral drugs for FIP have been identified, but many of these are expensive and not available in veterinary medicine. Hydroxychloroquine (HCQ) is a drug approved by several countries to treat malaria and immune-mediated diseases in humans, and its antiviral effects on other viral infections (e.g., SARS-CoV-2, dengue virus) have been confirmed. We investigated whether HCQ in association with interferon-omega (IFN-omega) is effective for FIPV in vitro. A total of 100 muM of HCQ significantly inhibited the replication of types I and II FIPV. Interestingly, the combination of 100 muM of HCQ and 10(4) U/mL of recombinant feline IFN-omega (rfIFN-omega, veterinary registered drug) increased its antiviral activity against type I FIPV infection. Our study suggested that HCQ and rfIFN-omega are applicable for treatment of FIP. Further clinical studies are needed to verify the combination of HCQ and rIFN-omega will be effective and safe treatment for cats with FIP."],"journal":"Viruses","authors":["Takano, Tomomi","Satoh, Kumi","Doki, Tomoyoshi","Tanabe, Taishi","Hohdatsu, Tsutomu"],"date":"2020-05-28T11:00:00Z","year":2020,"_id":"32456286","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.3390/v12050576","keywords":["feline coronavirus","feline infectious peritonitis","hydroxychloroquine","interferon"],"locations":["Feline","Hydroxychloroquine"],"e_drugs":["Hydroxychloroquine"],"topics":["Treatment"],"weight":1,"_version_":1667967699063406592,"score":286.68127},{"pmid":32333818,"title":"COVID-19: lambda interferon against viral load and hyperinflammation.","text":["COVID-19: lambda interferon against viral load and hyperinflammation.","Coronavirus Disease 2019 (COVID-19), triggered by the betacoronavirus SARS-CoV-2, has become one of the worst pandemics of our time that has already caused more than 183,470 deaths [JHU data-23/04/2020, https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9 ecf6]. Effective therapeutic approaches are urgently needed to reduce the spread of the virus and its death toll. Here, we assess the possibility of using interferon lambda (IFNlambda), a third type of interferon sharing low homology with type I IFNs and IL-10, for treating COVID-19 patients. We discuss the unique role of IFNlambda in fine-tuning antiviral immunity in the respiratory tract to achieve optimal protection and minimal host damage and review early evidence that SARS-CoV-2 may impair IFNlambda induction, leading to a delayed type I IFN-dominated response that triggers hyperinflammation and severe disease. We also consider the potential windows of opportunity for therapeutic intervention with IFNlambda and potential safety considerations. We conclude that IFNlambda constitutes a promising therapeutic agent for reducing viral presence and hyperinflammation in a single shot to prevent the devastating consequences of COVID-19 such as pneumonia and acute respiratory distress syndrome (ARDS).","EMBO Mol Med","Andreakos, Evangelos","Tsiodras, Sotirios","32333818"],"abstract":["Coronavirus Disease 2019 (COVID-19), triggered by the betacoronavirus SARS-CoV-2, has become one of the worst pandemics of our time that has already caused more than 183,470 deaths [JHU data-23/04/2020, https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9 ecf6]. Effective therapeutic approaches are urgently needed to reduce the spread of the virus and its death toll. Here, we assess the possibility of using interferon lambda (IFNlambda), a third type of interferon sharing low homology with type I IFNs and IL-10, for treating COVID-19 patients. We discuss the unique role of IFNlambda in fine-tuning antiviral immunity in the respiratory tract to achieve optimal protection and minimal host damage and review early evidence that SARS-CoV-2 may impair IFNlambda induction, leading to a delayed type I IFN-dominated response that triggers hyperinflammation and severe disease. We also consider the potential windows of opportunity for therapeutic intervention with IFNlambda and potential safety considerations. We conclude that IFNlambda constitutes a promising therapeutic agent for reducing viral presence and hyperinflammation in a single shot to prevent the devastating consequences of COVID-19 such as pneumonia and acute respiratory distress syndrome (ARDS)."],"journal":"EMBO Mol Med","authors":["Andreakos, Evangelos","Tsiodras, Sotirios"],"date":"2020-04-26T11:00:00Z","year":2020,"_id":"32333818","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.15252/emmm.202012465","keywords":["covid-19","cytokine storm","hyperinflammation","interferon","viral infection"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138493945905152,"score":265.1793},{"pmid":32459003,"title":"A Role for Retinoids in The Treatment of Covid-19?","text":["A Role for Retinoids in The Treatment of Covid-19?","The 2020 global outbreak of the novel coronavirus (SARS-CoV-2 or Covid-19) is a serious threat to international health and thus there is an urgent need for discovery of novel therapies or use of repurposed drugs that can make a significant impact on slowing the spread of the virus. Type 1 interferons (IFN-I) are a family cytokines of the early innate immune response to viruses that are being tested against SARS-CoV-2. However coronaviruses similar to SARS-CoV-2 can suppress host IFN-I anti-viral responses. Retinoids are a family molecules related to vitamin A that possess robust immune modulating properties, including the ability to increase and potentiate the actions of IFN-I. Therefore adjuvants such as retinoids, capable of increasing IFN-I mediated anti-viral responses should be tested in combinations of IFN-I and anti-viral drugs in pre-clinical studies of SARS-CoV-2.","Clin Exp Pharmacol Physiol","Trasino, Steven E","32459003"],"abstract":["The 2020 global outbreak of the novel coronavirus (SARS-CoV-2 or Covid-19) is a serious threat to international health and thus there is an urgent need for discovery of novel therapies or use of repurposed drugs that can make a significant impact on slowing the spread of the virus. Type 1 interferons (IFN-I) are a family cytokines of the early innate immune response to viruses that are being tested against SARS-CoV-2. However coronaviruses similar to SARS-CoV-2 can suppress host IFN-I anti-viral responses. Retinoids are a family molecules related to vitamin A that possess robust immune modulating properties, including the ability to increase and potentiate the actions of IFN-I. Therefore adjuvants such as retinoids, capable of increasing IFN-I mediated anti-viral responses should be tested in combinations of IFN-I and anti-viral drugs in pre-clinical studies of SARS-CoV-2."],"journal":"Clin Exp Pharmacol Physiol","authors":["Trasino, Steven E"],"date":"2020-05-28T11:00:00Z","year":2020,"_id":"32459003","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1111/1440-1681.13354","keywords":["covid-19","ifn-i","rig-i","sars-cov-2","interferons","retinoids","vitamin a"],"e_drugs":["Retinoids","Vitamin A"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667967698839011328,"score":253.33237}]}